THE discovery that single-gene manipulations can significantly modulate longevity is arguably the major breakthrough in biogerontology thus far ([@bib29]). Genetic manipulations of aging in mice are crucial to gather insights into the underlying mechanisms of aging ([@bib13]), to discover pathways modulating longevity ([@bib17]), and to identify candidate genes for drug discovery ([@bib15]; [@bib4]). Moreover, the manipulation of the aging process in mammalian models (particularly mice) via genetic manipulation (gene knockouts, over expression, *etc*.) is crucial to test mechanistic hypotheses of aging ([@bib12]). However, determining if such genetic interventions actually affect the aging process and not some other factor(s) of health is not always straight forward. For example, should a genetic intervention reduce an organism's resistance to disease, this could conceivably reduce the life span of the organism, although the rate of aging would not have been affected. Differentiating between genetic interventions that affect the life span of an organism through altered health as opposed to changes in the rate of aging is therefore essential to gain insights on aging and determine interventions with wide-ranging effects ([@bib23]; [@bib14]).

There are two fundamental methods to determine if a life-extending genetic intervention has altered the rate of aging rather than general health. One can track the onset and progression of age-related ailments and physiological degeneration to determine if there is a shift in the onset and progression of the ailments. In addition, efforts have been made to quantify aging rates with mathematical models. The Gompertz law of mortality:$$R_{m{(t)}} = R_{0}e^{\alpha t},$$where *R~m(t)~* is the hazard or mortality rate (likelihood of death at any time), *t* is age, *R~0~* is the age-independent mortality component, and α is the age-specific exponential coefficient, describes how the hazard rate increases exponentially with age ([@bib19]). From the Gompertz parameters, the mortality rate doubling time (MRDT) can be calculated. As defined by [@bib18]), the MRDT is the amount of time it takes for the mortality rate to double for a given cohort. A change in MRDT indicates a change in the demographic rate of aging, which is not a perfect reflection of biological aging but a metric that correlates with physiological deterioration and health ([@bib18]; [@bib14]). Although some mouse studies have investigated MRDT ([@bib24]; [@bib31]), many authors still often assume that changes in the life span of mice following a genetic intervention directly equate to changes in the rate of aging, leading to the misrepresentation of certain genes as having a causal role in aging, when in reality they do not.

Many studies have reported altered median and/or maximum life span as a result of an intervention, but life span alterations may have a number of causes, including altered age at onset of senescence and age-independent mortality ([@bib44]). To address this lack of distinction, we previously used linear regression to fit the Gompertz model to longevity data from published mouse studies, and statistically compared the rates of aging in these cohorts ([@bib14]). For example, we showed that caloric restriction increases the MRDT and thus retards the demographic rate of aging ([@bib14]). Here, the same methodology was employed to reassess mouse longevity data published since 2005 and to identify which genes are more important in determining the demographic rate of aging. Lastly, we perform a meta-analysis combining the data from the present study and from our 2005 analysis to investigate patterns in how longevity changes correlate with changes in demographic rates of aging.

Methods {#s1}
=======

Data selection and extraction {#s2}
-----------------------------

Studies published since 2005 were selected since studies published up to 2005 were analyzed previously ([@bib14]). Genes were selected from the GenAge database, build 17 ([@bib55]). GenAge already excludes genes extending life span in short-lived (or disease) mutants or conditions. In addition, some genes were excluded as they could not be studied for demographic parameters (some genes could not be properly fitted to the Gompertz model and some studies lacked full life span data, while other studies lacked sufficient cohort size). A total of 54 genetic manipulations could be properly analyzed (primarily single-gene manipulations but also some manipulations involving more than one gene): 30 genetic manipulations that extended mouse life span ([Table 1](#t1){ref-type="table"}) and 24 genetic manipulations that reduced life span ([Table 2](#t2){ref-type="table"}).

###### Mortality and life span statistics of genetically altered mouse strains with extended life span

  Gene or protein   Type                    Strain               Gender   *n*   *t50* (yr)   *tmax* (yr)    Reference
  ----------------- ----------------------- -------------------- -------- ----- ------------ -------------- -----------
  Adcy5             WT                      129/SvJ-C57BL/6      M & F    25    2.08         2.75           [@bib66]
                    −/−                                          M & F    13    2.75         3.08           
  Agrt1a            WT                      C57BL/6 × 129/SvEv   M        10    2.08         2.41           [@bib5]
                    −/−                                          M        20    2.63         3.00           
  Arf/p53           WT                      C57BL/6J                      111   2.31         3.30           [@bib37]
                    s-Arf/p53                                             25    2.63         3.03           
  Atg5              WT                      C57BL/6                       65    1.93         2.14           [@bib45]
                    Atg5-Tg                                               70    2.26         2.52           
  BubR1             WT                      C57BL/6-SV129        M:30     60    1.72         2.9            [@bib3]
  F: 30                                                                                                     
                    mBubR1-Tg                                    M:29     57    2.02         3.42           
  F:28                                                                                                      
  Cat               WT                      4033                 M & F    44    2.16         2.83           [@bib49]
                    MCAT                    4033                 M & F    20    2.58         3.10           
                    WT                      4403                 M & F    58    2.18         3.06           
                    MCAT                    4403                 M & F    42    2.60         3.33           
  Cisd2             WT (M)                  C57BL/6              M        40    2.25         2.90           [@bib64]
                    Cisd2-Tg (M)                                 M        34    2.69         3.07           
                    WT (F)                                       F        25    2.27         2.50           
                    Cisd2-Tg (F)                                 F        21    2.74         3.25           
  Clk-1             WT                      129Sv/J              F        12    2.01         2.30           [@bib35]
                    +/−                                          F        10    2.34         2.54           
  Dgat1             WT                      C57BL/6J             F        30    2.04         2.81           [@bib52]
                    −/−                                          F        30    2.58         3.05           
  Esp8              WT                      C57BL/6              M:13     29    1.74         2.72           [@bib57]
  F:16                                                                                                      
                    −/−                                          M:20     39    2.16         3.00           
  F:19                                                                                                      
  FGF21             WT                      C57Bl/6J             M:32     67    2.34         3.56           [@bib70]
  F:35                                                                                                      
                    FGF21-Tg                                     M:37     77    3.18         NR (\> 3.65)   
  F:40                                                                                                      
  Ghrh              WT                      C57BL/6              M:56     108   1.75         3.20           [@bib54]
  × 129SV           F:52                                                                                    
                    KO                                           M:39     97    2.55         3.58           
  F:58                                                                                                      
  Gpx4              WT                      C57BL/6                       50    2.63         3.34           [@bib46]
                    +/--                                                  50    2.83         3.17           
  hMTH1             WT                      C57BL/6              M        42    2.17         2.64           [@bib11]
                    hMTH1-Tg                                     M        34    2.51         3.21           
  Htt               WT                      129/Sv-              M:1      15    2.34         2.93           [@bib71]
  F:14                                                                                                      
                    ΔQ/ΔQ                                        M:2      15    2.76         3.43           
  F:13                                                                                                      
  Igf1              WT                      FVB                  M        39    1.97         3.17           [@bib34]
                    Igf1-Tg                                      M        38    2.43         3.42           
  IκB-α             MBH-GFP                 C57BL/6                       23    2.41         2.91           [@bib68]
                    MBH-IκB-α                                             31    2.64         3.09           
  Irs1              WT (F)                  C57BL/6              F        21    2.02         2.86           [@bib50]
                    −/− (F)                                      F        14    2.66         3.61           
  Irs2              WT                      C57BL/6J             M:21     93    2.36         2.86           [@bib56]
  F:30                                                                                                      
                    Brain-specific +/−                           M:27     65    2.81         3.34           
  F:60                                                                                                      
  Mif               WT                      C57BL/6J × 129/SvJ   F        24    2.01         2.70           [@bib22]
                    −/−                                          F        39    2.45         3.51           
  mTOR              WT                      129 × C57BL/6        M & F    34    2.13         3.14           [@bib65]
                    KO                                           M & F    43    2.51         3.14           
  Myc               WT (F)                  C57BL/6              F        37    2.23         2.86           [@bib25]
                    +/− (F)                                      F        39    2.68         3.58           
                    WT (M)                                       M        42    2.41         3.00           
                    +/− (M)                                      M        42    2.66         3.26           
  PAPP-A            WT                      C57BL6 × 129SV/E     M & F    21    1.84         2.44           [@bib9]
                    −/−                                          M & F    20    2.64         3.11           
  Pten              WT                      C57BL/6              M:49     112   2.17         2.92           [@bib42]
  × CBA             F:63                                                                                    
                    Pten-Tg                                      M:32     64    2.44         3.21           
  F:32                                                                                                      
  RpS6K1            WT                      C57BL/6              M:26     49    2.23         3.00           [@bib50]
  F:23                                                                                                      
                    −/−                                          M:19     48    2.64         3.40           
  F:29                                                                                                      
  RIIβ              WT                      C57BL/6 (males)      M        20    2.42         2.79           [@bib16]
                    RIIB −/−                                     M        20    2.75         3.07           
  Sirt1             WT                      C57BL/6              M & F    31    2.30         3.01           [@bib48]
                    Brain-specific Tg                            M & F    34    2.56         3.11           
  Slc13a1           WT (M)                  C57BL/6J × 129/SV    M        21    1.93         2.60           [@bib36]
                    Nas1 −/− (M)                                 M        25    2.54         3.30           
                    WT (F)                                       F        34    1.68         2.50           
                    Nas1 −/− (F)                                 F        38    2.06         2.90           
  Surf1             WT                      BDF1 × cre           M:23     48    1.78         NR             [@bib10]
  F:25                                                                                                      
                    −/−                                          M:21     43    2.17         2.48           
  F:22                                                                                                      
  Tert              Sp53                    C57BL/6 × DBA/2      M & F    68    2.13         3.09           [@bib58]
                    Sp53/TgTert                                  M & F    56    2.36         3.22           
                    Sp53/Sp16/SArf                               M & F    39    2.38         3.18           
                    Sp53/Sp16/SArf/TgTert                        M & F    27    2.38         3.26           

*t50*, median life span; *tmax*, maximum life span; yr, year; WT, wild-type; M, male; F, female; Tg, transgenic; NR, not reported; KO, knockout.

###### Mortality and life span statistics of genetically altered mouse strains with shortened life span

  Gene or protein   Type                   Strain                Gender   *n*   *t50* (yr)   *tmax* (yr)   Reference
  ----------------- ---------------------- --------------------- -------- ----- ------------ ------------- -----------
  Aag, Atm, Mgmt    WT                     C57BL/6               M & F    37    2.03         2.87          [@bib38]
                    Aag --/--                                    M & F    29    1.80         2.50          
                    Mgmt --/--                                   M & F    50    1.92         2.77          
                    Atm --/--                                    M & F    19    0.56         1.37          
                    Aag --/-- Mgmt --/--                         M & F    31    1.67         2.71          
  ATR               WT                                           M & F    20    NR           NR            [@bib40]
                    ATR^s/s^                                     M & F    27    0.42         0.65          
  Brca1             WT                     129O1a × C57BL/6J     F        32    2.15         2.56          [@bib27]
                    +/−                                          F        26    1.94         2.53          
  Bub3 + Rae1       WT                     129Sv/E × C57BL/6     N/A      70    2.08         NR            [@bib2]
                    +/−, +/−                                     N/A      100   1.84         NR            
  Casp2             WT                     C57BL/6               N/A      64    2.62         3.51          [@bib69]
                    −/−                                          N/A      64    2.62         3.25          
  Cdc42             WT                     C57BL/6^+/−^ 129/Sv   M & F    16    2.28         2.49          [@bib62]
                    −/−                                          M & F    21    1.09         2.50          
  Cisd2             WT                     C57BL/6 (B6)          M & F    49    2.09         2.53          [@bib8]
                    Cisd2−/−                                     M & F    16    1.28         2.15          
  Cisd2             WT                     C57BL/6               M        40    2.25         2.90          [@bib64]
                    +/--                                         M        51    2.05         2.57          
                    --/--                                        M        27    1.76         2.32          
                    WT                                           F        25    2.27         2.50          
                    +/--                                         F        47    1.92         2.50          
                    --/--                                        F        49    1.83         2.94          
  DNA pol β         WT                     C57BL/6               M        60    2.54         3.19          [@bib6]
                    +/--                                         M        67    2.54         3.19          
  Fgf-23            −/−                    Sv129J                M & F    15    0.12         0.26          [@bib47]
  Fn1               WT                     C57BL/6               M        39    2.43         NR            [@bib41]
                    Fn1^EDA\ −/−^                                M        53    1.93         NR            
  HtrA2/Omi         mnd2/+;Tg              C57BL/6J              M & F    23    N/A          N/A           [@bib28]
                    mnd2/mnd2;Tg                                 M & F    21    1.28         1.50          
  Htr1b             WT                                           N/A      21    2.58         3.14          [@bib51]
                    −/−                                          N/A      24    2.05         2.75          
  IKK-β             MBH-GFP                C57BL/6               M        23    2.41         2.91          [@bib68]
                    N/*I*kbkb^l/l^                               M        24    2.23         2.56          
  junD              WT                     N/A                   M & F    35    1.91         2.41          [@bib32]
                    JunD^−/−^              N/A                   M & F    35    1.66         2.17          
  Msh2              WT                     129S/SvEvTac          M & F    51    NR           NR            [@bib63]
                    −/−                                          M & F    32    0.58         0.92          
  Pasg              −/−                    129/SvJ/C57BL/6J      N/A      63    0.01         0.07          [@bib53]
  Pparg             WT                                           F        25    2.35         2.68          [@bib1]
                    Pparg2^−/−^                                  F        26    2.14         2.62          
  Sirt7             WT                     C57Bl/6 × 129Sv       M        98    NR           NR            [@bib59]
                    −/−                                          M        32    0.74         1.60          
  Socs2             WT                     C57BL/6J × FVB        M & F    123   2.10         3.00          [@bib7]
                    hg/hg                                        M & F    146   1.33         2.59          
  Stub1             WT                     C57BL/6 × 129SvEv     M:82     82    2.08         NR            [@bib39]
  F:84                                                                                                     
                    −/−                                          M:58     128   0.89         NR            
  F:45                                                                                                     
  Trp63             WT                     K5CrePR1              NR       74    2.23         3.00          [@bib30]
                    +/−                                          NR       104   1.74         2.25          
  Xrcc5             WT                                           NR       47    2.04         2.40          [@bib60]
                    Ku86 −/−                                     NR       89    0.79         1.75          
  Xrcc6             WT                                           M & F    27    2.17         2.80          [@bib33]
                    Ku70 −/−                                     M & F    43    0.69         1.45          

*t50*, median life span; *tmax*, maximum life span; yr, year; WT, wild-type; M, male; F, female; Tg, transgenic; NR, not reported;

Mortality data were extracted from published studies. WebPlotDigitizer, an online graph digitizer application (<https://automeris.io/WebPlotDigitizer/>), was used to extract raw data from survival graphs in some cases. The digital imaging software package PaintShop Pro X3 (Corel Corporation, Ottawa, Canada) was used to extract age-specific survival data from published survivorship graphs (usually in the form of Kaplan--Meier survivorship curves). Percent survival was extracted at regular time intervals over the linear phase of these plots. Interval length was selected for each study individually to maximize the number of consecutive time points analyzed within this exponential phase.

Demographic analysis {#s3}
--------------------

The same methods and computer programs for the data gathering and analysis of [@bib14] were used. Once the mortality data were collected, the age-specific mortality (*q~x~*) was calculated as the number of mice alive (*T*~1~) at the beginning of a given time interval minus the number of mice alive (*T*~2~) at the end of that same time interval divided by *T*~1~ (*i.e.*, $\left( T1 - T2 \right)/{T1}$ = qx). The hazard rate (*hz*) for each individual time interval was calculated as *hz* = $\left. \left. \left( T1 - T2 \right)/\left( \left( T1 + T2 \right. \right. \right)/2 \right)$ or the number of animals dying in the interval divided by the average number of individuals alive in the interval. The aging rate was then calculated through use of the Gompertz equation: *R~m(t)~ = R~0~e*^α^*^t^*; where *R~m(t)~* is the chance of dying (the hazard rate) at age *t*, *R~0~* is the nonexponential factor in mortality, and α is the exponential parameter ([@bib20]). The Gompertz model was used because, as [@bib14]) asserted, the sample size (number of mice) in the majority of these experiments was small, meaning that other logarithmic methods of fitting models to mortality data may not provide the accuracy that the Gompertz model gives while retaining its simplicity. This point held true for the majority of genetic interventions tested herein and so it was decided that use of the Gompertz model remained a viable option for this analysis. From the Gompertz model, the weighted regression line (weighted by the number of animals dying at each interval) was calculated by *ln(R~m(t)~) = ln(R~0~) +* α*t*, which will also give the MRDT as ${0.693/\alpha}.$ To compare α between a given genetic intervention cohort and wild-type (WT) mice from the same lineage, a "dummy variables" test was employed as described ([@bib14]). As in [@bib14], the aim of this research was not to find the best fit model to describe the whole of the mortality curves, but rather to find if any previously published genetic interventions have a statistically significant effect on the exponential increase in mortality (α) and hence on the demographic rate of aging. Consequently, the simpler, nested Gompertz model was preferred ([@bib14]). Besides, data were only analyzed from the onset of the exponential increase in mortality, though typically \< 10% of animals were left out.

Statistical analysis {#s4}
--------------------

A "dummy variables" method was used to compare the slopes of the hazard functions obtained through linear regression for the WT and test cohorts and a two-tailed Student's *t*-test was applied to evaluate whether they were significantly different (*P* \< 0.05). Analysis was performed in SPSS version 22 (IBM) using our previous scripts ([@bib14]) (code available in the supplemental material and at <http://genomics.senescence.info/software/demographic.html>).

Data availability {#s5}
-----------------

The survival data used in this study is provided in the Supplemental Material, Tables S1 and S2 in [File S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1/FileS1.xlsx;). The SPSS code used is provided in [File S2](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1/FileS2.txt;).

Results {#s6}
=======

The Gompertz law of mortality describes the exponential increase in mortality rate with age. Modified versions of this function exist to model mortality deceleration observed at very young and very old ages; however, the simplest form was chosen to fit the mouse survivorship data in this study because the mouse cohorts are often small (*n* \< 50). The basic Gompertz model is described by only two parameters, so is more suitable for fitting data from smaller sample sizes ([@bib43]) and increases the ease of comparing aging rates between cohorts. Since mouse longevity data are largely presented in publications as Kaplan--Meier survival curves, the life spans were divided into discrete time intervals and then linear regression was used to calculate age-specific mortality rates for each interval (see *Methods*). This allowed an estimation of Gompertz parameters for each cohort that could be directly compared.

In this study, 54 previously published genetic manipulations that have been associated with alterations in mouse life span were analyzed; 30 manipulations previously reported as having a life span-extending effect ([Table 1](#t1){ref-type="table"}) and 24 that were previously reported as having a life span-reducing effect ([Table 2](#t2){ref-type="table"}). The aim of this study was to reassess genes that have been reported to regulate longevity in mice to ascertain which of them might exert this effect through regulating the rate of aging.

Analysis of life-extending gene manipulations {#s7}
---------------------------------------------

Of the 30 genetic manipulations previously reported as having life span-increasing effects, we found 13 genes to have a statistically significant effect on the demographic rate of aging ([Table 3](#t3){ref-type="table"}): *BubR1*, *Cisd2*, *Dgat1*, *Fgf21*, *Ghrh*, *Gpx4*, *hMTH1*, *Irs2*, *mTOR*, *Sirt1*, *Slc13a1*, *Surf1*, and *Tert*. However, surprisingly only two of these genes (*Cisd2* and *hMTH1*) retarded the demographic rate of aging. Full survival data are provided in the supplemental material (Table S1 in [File S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1/FileS1.xlsx;)).

###### Gompertz parameters for genetically altered mouse strains with extended life span from a regression line calculated by *ln(R~m(t)~) = ln(R~0~) +* α*t* (see *Methods*)

  Gene or protein                              Type                                              Strain               α      α SE    ln(R~0~)   *r*^2^   MRDT (yr)
  -------------------------------------------- ------------------------------------------------- -------------------- ------ ------- ---------- -------- -----------
  Adcy5                                        WT                                                129/SvJ-C57BL/6      3.87   0.94    −9.61      0.71     0.18
                                               −/−                                                                    5.95   0.34    −17.20     0.97     0.12
  Agrt1a                                       WT                                                C57BL/6 × 129/SvEv   5.20   1.21    −11.15     0.86     0.13
                                               −/−                                                                    3.95   1.30    −10.81     0.70     0.18
  Arf/p53                                      WT                                                C57BL/6J             2.88   0.32    −7.59      0.94     0.24
                                               s-Arf/p53                                                              2.80   0.44    −8.05      0.86     0.25
  Atg5                                         WT                                                C57BL/6              7.30   5.48    −14.40     0.47     0.10
                                               Atg5-Tg                                                                8.92   1.31    −21.54     0.82     0.08
  BubR1[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                C57BL/6-SV129        1.62   0.16    −5.42      0.92     0.43
                                               mBubR1-Tg                                                              2.61   0.097   −7.48      0.93     0.27
  Cat                                          WT                                                4033                 2.30   0.18    −6.40      0.81     0.30
                                               MCAT                                              C57BL/6J             3.00   0.59    −8.80      0.68     0.23
                                               WT                                                4403                 2.00   0.21    −5.93      0.62     0.35
                                               MCAT                                                                   2.20   0.20    −7.41      0.78     0.32
  Cisd2[*^a^*](#t3n1){ref-type="table-fn"}     WT male                                           C57BL/6              7.67   2.86    −17.79     0.71     0.09
                                               Cisd2-Tg male                                                          6.96   1.84    −19.39     0.83     0.10
                                               WT female                                                              6.62   2.27    −14.43     0.90     0.10
                                               Cisd2-Tg female                                                        2.40   0.59    −7.10      0.74     0.29
  Clk-1                                        WT                                                129Sv/J              3.09   0.64    −6.05      0.89     0.22
                                               +/−                                                                    2.49   0.92    −5.95      0.64     0.28
  Dgat1[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                C57BL/6J             1.92   0.53    −5.12      0.66     0.36
                                               −/−                                                                    3.56   0.20    −9.63      0.99     0.19
  Esp8                                         WT                                                C57BL/6              1.50   0.22    −3.70      0.73     0.46
                                               −/−                                                                    1.98   0.18    −5.15      0.81     0.35
  FGF21[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                C57Bl/6J             1.82   0.35    −5.66      0.82     0.38
                                               FGF21-Tg                                                               2.04   0.40    −7.89      0.87     0.34
  Ghrh[*^a^*](#t3n1){ref-type="table-fn"}      WT                                                C57BL/6 × 129SV      1.31   0.18    −3.55      0.90     0.53
                                               KO                                                                     1.53   0.17    −5.12      0.94     0.45
  Gpx4[*^a^*](#t3n1){ref-type="table-fn"}      WT                                                C57BL/6              3.11   1.08    −9.18      0.73     0.22
                                               +/--                                                                   5.43   0.72    −15.77     0.95     0.13
  hMTH1[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                C57BL/6              3.50   0.65    −8.78      0.81     0.20
                                               hMTH1-Tg                                                               2.29   0.47    −6.91      0.72     0.30
  Htt                                          WT                                                129/Sv-              2.30   1.01    −6.03      0.56     0.30
                                               ΔQ /ΔQ                                                                 1.80   0.51    −5.19      0.81     0.39
  Igf1                                         WT                                                FVB                  1.06   0.26    −3.02      0.74     0.65
                                               Igf1                                                                   1.35   0.25    −4.43      0.77     0.51
  IκB-α                                        MBH-GFP                                           C57BL/6              4.15   0.74    −10.75     0.65     0.17
                                               MBH-DN IB-α                                                            4.43   0.76    −12.86     0.62     0.16
  Irs1                                         WT (female)                                       C57BL/6              2.18   0.26    −5.00      0.80     0.32
                                               −/− (female)                                                           1.94   0.31    −6.45      0.71     0.36
  Irs2[*^a^*](#t3n1){ref-type="table-fn"}      WT                                                C57BL/6J             2.99   0.13    −7.29      0.87     0.23
                                               Brain-specific +/−                                                     6.37   0.33    −17.73     0.85     0.11
  Mif                                          WT                                                C57BL/6J × 129/SvJ   2.45   0.40    −6.08      0.84     0.28
                                               −/−                                                                    1.90   0.31    −6.02      0.82     0.37
  mTOR[*^a^*](#t3n1){ref-type="table-fn"}      WT                                                129 × C57BL/6        1.47   0.45    −4.46      0.68     0.47
                                               KO                                                                     2.41   0.15    −6.94      0.98     0.29
  Myc                                          WT female                                         C57BL/6              2.19   0.55    −5.88      0.76     0.32
                                               +/-- female                                                            3.19   1.05    −9.64      0.70     0.22
                                               WT male                                                                2.53   0.21    −7.06      0.96     0.27
                                               +/-- male                                                              2.55   0.36    −7.75      0.90     0.27
  PAPP-A                                       WT                                                C57BL6 × 129SV/E     2.33   0.35    −5.28      0.71     0.30
                                               −/−                                                                    2.67   0.32    −7.39      0.80     0.26
  Pten                                         WT                                                C57BL/6 × CBA        2.33   0.14    −5.83      0.97     0.30
                                               Pten-Tg                                                                2.52   0.24    −7.07      0.95     0.27
  RpS6K1                                       WT                                                C57BL/6              1.81   0.069   −4.64      0.93     0.38
                                               −/−                                                                    1.73   0.056   −5.30      0.91     0.40
  RIIβ                                         WT                                                C57BL/6 (males)      3.00   0.31    −7.68      0.85     0.23
                                               RIIB −/−                                                               3.55   0.34    −10.09     0.88     0.20
  Sirt1[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                C57BL/6              2.45   0.49    −7.20      0.81     0.28
                                               Brain-specific Tg                                                      3.63   0.63    −10.71     0.83     0.19
  Slc13a1[*^a^*](#t3n1){ref-type="table-fn"}   WT (male)                                         C57BL/6J × 129/SV    1.79   0.37    −4.34      0.83     0.39
                                               Nas1 −/− (male)                                                        1.70   0.47    −5.02      0.72     0.41
                                               WT (female)                                                            0.87   0.13    −2.95      0.86     0.80
                                               Nas1 −/− (female)                                                      1.69   0.29    −4.31      0.85     0.41
  Surf1[*^a^*](#t3n1){ref-type="table-fn"}     WT                                                BDF1 × cre           2.19   0.39    −4.81      0.86     0.32
                                               −/−                                                                    3.41   0.47    −7.82      0.96     0.20
  TgTert[*^a^*](#t3n1){ref-type="table-fn"}    Sp53                                              C57BL/6 × DBA/2      2.74   0.33    −6.51      0.95     0.25
                                               Sp53[*^a^*](#t3n1){ref-type="table-fn"} /TgTert                        3.34   0.41    −8.14      0.94     0.21
                                               Sp53/Sp16/SArf                                                         1.47   0.58    −4.86      0.52     0.47
                                               Sp53/Sp16/SArf/TgTert                                                  2.08   0.65    −7.24      0.77     0.33

α, age-specific exponential coefficient; ln(R0), nonexponential factor in mortality; MRDT, mortality rate doubling time as in ${0.693/\alpha};$ yr, year; WT, wild-type; Tg, transgenic; KO, knockout.

Indicates genes for which the changes in MRDT were statistically significant (*P* \< 0.05).

A few notable examples are worth emphasizing. Transgenic expression of *Cisd2* in female mice produced persistent expression of the Cisd2 protein in contrast to levels in WT mice, which diminished with age ([@bib64]). Our analysis showed that this resulted in a nearly twofold higher MRDT compared to that of female WT controls, consistent with a difference between the Gompertz curve gradients ([Figure 1A](#fig1){ref-type="fig"}). This suggests that *Cisd2* regulates the demographic rate of aging. However, the nature of the role of *Cisd2* in aging is confused by the fact that reduced expression of *Cisd2* in heterozygous and double-knockout female mice from the same study also resulted in a significantly increased MRDT (see [Table 4](#t4){ref-type="table"}), suggesting that reduced *Cisd2* expression also slowed the demographic rate of aging.

![Natural logarithm of mortality rates for wild-type (WT, blue diamonds) and experimental transgenic (Tg, red squares) cohorts. Lines represent estimated adult mortality trajectories based on Gompertz parameters for the WT (blue lines) and experimental (red lines) cohorts. (A) *Cisd2*. (B) *Sirt1*.](1617fig1){#fig1}

###### Gompertz parameters for genetically altered mouse strains with shortened life span from a regression line calculated by *ln(R~m(t)~) = ln(R~0~) +* α*t* (see *Methods*)

  Gene or protein                                     Type                                                      Strain                α       α SE   ln(R~0~)   *r*^2^   MRDT (yr)
  --------------------------------------------------- --------------------------------------------------------- --------------------- ------- ------ ---------- -------- -----------
  Aag, Atm, Mgmt[*^a^*](#t4n1){ref-type="table-fn"}   WT                                                        C57BL/6               3.81    0.82   −8.83      0.78     0.18
                                                      Aag --/--[*^a^*](#t4n1){ref-type="table-fn"}                                    2.20    1.04   −5.38      0.53     0.31
                                                      Mgmt --/--                                                                      3.08    0.50   −7.65      0.86     0.23
                                                      Atm --/--[*^a^*](#t4n1){ref-type="table-fn"}                                    2.21    1.03   −2.39      0.48     0.31
                                                      Aag --/-- Mgmt --/--[*^a^*](#t4n1){ref-type="table-fn"}                         1.66    0.41   −4.38      0.65     0.42
  ATR                                                 WT                                                        N/A                   N/A     N/A    N/A        N/A      N/A
                                                      ATR^s/s^                                                                        6.46    1.33   −3.38      0.86     0.11
  Brca1                                               WT                                                        129O1a × C57BL/6J     4.59    0.36   −10.01     0.98     0.15
                                                      +/− (female)                                                                    3.96    0.48   −8.06      0.97     0.17
  Bub3 + Rae1                                         WT                                                        129Sv/E × C57BL/6     1.54    0.34   −4.86      0.91     0.45
                                                      +/−, +/−                                                                        1.16    0.49   −3.72      0.61     0.60
  Casp2[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                        C57BL/6               1.46    0.31   −5.39      0.79     0.47
                                                      −/−                                                                             3.20    0.44   −9.44      0.91     0.22
  Cd42 GAP[*^a^*](#t4n1){ref-type="table-fn"}         WT                                                        C57BL/6^+/−^ 129/Sv   3.39    1.11   −8.16      0.61     0.20
                                                      −/−                                                                             1.24    1.44   −2.89      0.87     0.56
  Cisd2[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                        C57BL/6 (B6)          3.42    0.81   −8.37      0.64     0.20
                                                      Cisd2−/−                                                                        1.02    0.36   −2.10      0.66     0.68
  Cisd2[*^a^*](#t4n1){ref-type="table-fn"}            WT male                                                   C57BL/6               7.67    2.86   −17.79     0.71     0.09
                                                      +/-- male[*^a^*](#t4n1){ref-type="table-fn"}                                    4.06    1.26   −9.68      0.68     0.17
                                                      --/-- male                                                                      5.56    1.11   −11.06     0.86     0.12
                                                      WT female                                                                       6.62    2.27   −14.43     0.90     0.10
                                                      +/-- female[*^a^*](#t4n1){ref-type="table-fn"}                                  2.50    0.49   −5.69      0.81     0.28
                                                      --/-- female[*^a^*](#t4n1){ref-type="table-fn"}                                 2.44    0.40   −5.16      0.84     0.28
  DNA pol β                                           WT                                                        C57BL/6               3.06    0.59   −9.42      0.79     0.23
                                                      +/--                                                                            3.11    0.65   −9.11      0.82     0.22
  Fgf-23                                              −/−                                                       Sv129J                6.48    N/A    −1.76      0.41     0.11
  Fn1[*^a^*](#t4n1){ref-type="table-fn"}              WT                                                        C57BL/6               1.49    0.48   −5.22      0.62     0.46
                                                      Fn1^EDA\ −/−^                                                                   2.73    0.56   −6.01      0.82     0.25
  Htr1b[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                                              4.95    0.83   −13.74     0.90     0.14
                                                      −/−                                                                             4.06    0.46   −9.56      0.94     0.17
  HtrA2/Omi                                           mnd2/mnd2;Tg                                              C57BL/6J              N/A     N/A    N/A        N/A      N/A
                                                      mnd2/+;Tg                                                                       5.38    1.69   −7.16      0.84     0.13
  IKK-β[*^a^*](#t4n1){ref-type="table-fn"}            MBH-GFP                                                   C57BL/6               4.78    1.09   −12.43     0.76     0.15
                                                      N/*I*kbkb^l/l^                                                                  6.03    0.84   −14.37     0.90     0.12
  junD[*^a^*](#t4n1){ref-type="table-fn"}             WT                                                        N/A                   2.67    0.77   −5.85      0.75     0.26
                                                      JunD^−/−^                                                 N/A                   3.89    0.57   −7.47      0.90     0.18
  Msh2                                                WT                                                        129S/SvEvTac          N/A     N/A    N/A        N/A      N/A
                                                      −/−                                                                             1.69    N/A    −2.69      0.26     0.41
  Pasg                                                −/−                                                       129/SvJ/C57BL/6J      64.15   N/A    −2.55      0.75     0.01
  Pparg[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                                              4.43    0.53   −11.02     0.93     0.16
                                                      Pparg2^−/−^                                                                     2.59    0.29   −6.93      0.92     0.27
  Sirt7                                               WT                                                        C57Bl/6 × 129Sv       N/A     N/A    N/A        N/A      N/A
                                                      −/−                                                                             2.16           −2.01      0.71     0.32
  Socs2[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                        C57BL/6J × FVB        2.14    0.40   −5.16      0.85     0.32
                                                      hg/hg                                                                           1.43    0.33   −2.69      0.73     0.48
  Stub1[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                        C57BL/6 × 129SvEv     0.80    0.40   −3.78      0.44     0.87
                                                      −/−                                                                             1.31    0.44   −2.46      0.59     0.53
  Trp63[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                        K5CrePR1              2.90    N/A    −7.47      0.86     0.24
                                                      +/−                                                                             1.75    N/A    −3.72      0.83     0.40
  Xrcc5[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                                              2.68    0.35   −5.84      0.94     0.26
                                                      Ku86 −/−                                                                        1.63    0.38   −2.34      0.70     0.43
  Xrcc6[*^a^*](#t4n1){ref-type="table-fn"}            WT                                                                              1.92    0.30   −4.98      0.89     0.36
                                                      Ku70 −/−                                                                        1.39    0.44   −1.49      0.83     0.50

α, age-specific exponential coefficient; ln(R0), nonexponential factor in mortality; MRDT, mortality rate doubling time as in ${0.693/\alpha};$ yr, year; WT, wild-type; N/A, not applicable; Tg, transgenic.

Indicates genes for which the changes in MRDT were statistically significant (*P* \< 0.05).

Most genes examined did not impact on MRDT, and a few even reduced the MRDT. Of note, regarding *Sirt1*, a 33% reduction in MRDT was observed for transgenic mice with brain-specific overexpression of this gene. This is supported by a visible change in the slope of the Gompertz curve ([Figure 1B](#fig1){ref-type="fig"}). It therefore appears that the increases in median and maximum life span reported ([@bib48]) are not mediated by a decrease in the rate of aging. Instead, it appears that the longevity extension in this cohort occurred through delayed onset of the exponential increase in mortality rate. Likewise, mice constitutively overexpressing both the tumor suppressor *p53* and telomerase reverse transcriptase (*Tert*) exhibited enhanced 3-year survival rates compared to super-p53 mice expressing only the additional transgenic copy of *p53* ([@bib58]). Interestingly, our analysis indicates that the MRDT of the former cohort was modestly reduced by 18% compared to that of the control mice, which suggests that the life-extending effect of *Tert* overexpression is due to a reduced *R~0~* rather than to a slower demographic rate of aging. By contrast, mice overexpressing *Tert* in addition to *p16*, *Arf*, and *p53* have a higher MRDT, although this difference was not statistically significant ([Table 3](#t3){ref-type="table"}).

Analysis of genes reported to reduce life span and/or accelerate aging {#s8}
----------------------------------------------------------------------

Interventions that reduce life span by increasing the rate of aging would be expected to reduce the MRDT. Of the 24 genes previously reported as having life span-reducing effects, we found 15 to have a statistically significant effect on the demographic rate of aging ([Table 4](#t4){ref-type="table"}): *Aag/Atm/Mgmt*, *Casp2*, *Cisd2* (2× studies), *Cdc42GAP*, *Fn1*, *Htr1b*, *IKK*-β, *JunD*, *Pparg*, *Socs2*, *Stub1*, *Trp63*, *Xrcc5*, and *Xrcc6*. Five of these (*Casp2*, *Fn1*, *IKK*-β, *JunD*, and *Stub1*) accelerated demographic aging. Full survival data are provided in the supplemental material (Table S2 in [File S1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1/FileS1.xlsx;)).

As before, a few notable examples are worth highlighting. Mice carrying a double knockout of *Casp2* exhibited a 54% lower MRDT than WT littermates ([Figure 2A](#fig2){ref-type="fig"}). Therefore, as initially reported by [@bib69], *Casp2* accelerates the rate of aging in mice. [@bib69] used several methods including a thorough detailing of the progression of age-related ailments (such as gradual hair and increased bone loss) to detail the rate of aging of the *Casp2* knockout and their WT littermates, and our new research (using statistical demographic methods) has drawn the same conclusions.

![Natural logarithm of mortality rates for wild-type (WT, blue diamonds) and experimental (red squares) cohorts. Lines represent estimated adult mortality trajectories based on Gompertz parameters for the WT (blue lines) and experimental (red lines) cohorts. KO, knockout. (A) *Casp2*; (B) *MBH-IKK*-β; (C) *Xrcc6*; and (D) *Htr1b* with the green line and circles representing an alternative for the WT cohort (see text for details).](1617fig2){#fig2}

Another gene manipulation that significantly reduced MRDT involved IκB kinase-β (IKK-β), which is involved in the activation of NF-κB. NF-κB activity in the hypothalamus of mice increases with age and mice expressing constitutively active IKK-β in the mediobasal hypothalamus (MBH) exhibited shortened life spans ([@bib68]). The MRDT for MBH-IKK-β mice was reduced by 21% compared to that of control mice. The fitted Gompertz curves showed an increased gradient ([Figure 2B](#fig2){ref-type="fig"}), providing evidence that activated hypothalamic NF-κB promotes faster aging. As the authors note, this is interesting because it suggests that a single organ, the hypothalamus, is important in regulating aging of the whole animal.

As in life-extending interventions, most genes did not impact on MRDT and some even had an opposite effect than expected. For example, *Xrcc6* −/− (also known as *Ku70* −/−) mice had shortened life spans compared to WT controls ([@bib33]). Fitting the survival data from this study produced mortality curves with visibly different starting ages ([Figure 2C](#fig2){ref-type="fig"}) and the MRDT of the *Xrcc6* −/− mice was 38% larger than that of the WT cohort. This points to a slower demographic rate of aging in the *Xrcc6* −/− mice. It should be noted that animals that died in the first 3 weeks were censored in the original study because *Ku* mutant mice frequently do not survive to weaning age. Including these animals would have altered the survival plots and might therefore have impacted on the outcome of this analysis.

Finally, reassessment of the survival data of *Htr1b*−/− mice showed that they have a 22% increased MRDT compared to WT controls. This can be seen as a slight difference in the slopes of the Gompertz curves ([Figure 2D](#fig2){ref-type="fig"}). Reduced longevity was reported in *Htr1b*−/− mice ([@bib51]) and our results support the conclusion that *Htr1b* deficiency produces a significantly decreased demographic rate of aging; however, the cohorts used in this study were small (*n* = 21 for WT and *n* = 24 for *Htr1b*−/−). If we increase the period from which data were extracted for the *Htr1b*−/− mice and exclude outliers of the Gompertz curve, the difference in MRDT is no longer significant. This result highlights the differences that one can obtain in this type of analysis by changing subjective parameters, in particular for smaller cohorts.

Longevity effects are driven by aging-independent mortality {#s9}
-----------------------------------------------------------

Looking at our data set as a whole ([Table 1](#t1){ref-type="table"}, [Table 2](#t2){ref-type="table"}, [Table 3](#t3){ref-type="table"}, and [Table 4](#t4){ref-type="table"}), it is clear that studies are highly variable. Of note, cohort size ranges from 10 to 146 animals. Moreover, while the SD of median life span (*t50*) was only 13% for life span-extending manipulations (range 1.68--3.18 years), for life span-reducing manipulations it was 39% (0.01--2.62 years range). For maximum life span (*tmax*), SD was 11% for life span-extending manipulations (range 2.14--3.61 years) and 33% (0.07--3.51 years range) for life span-reducing manipulations. This is not surprising given that life-shortening manipulations can have greater effect sizes than life-extending manipulations, but it also introduces noise in demographic aging estimates, in particular for life span-shortening manipulations.

Even looking only at WT controls from the C57BL/6 strain (15 studies), the most common strain in our analysis, the range of *t50* was 1.74--2.63 years while *tmax* ranged from 2.14 to 3.56. While *tmax* is influenced by cohort size, *t50* is not and, therefore, this substantial variation for WT mice of the same genetic background suggests that considerable variation is introduced by differences in animal husbandry and stochastic factors. Relative SD for α and ln(*R~0~*) in C57BL/6 cohorts were, respectively, 57 and 42%.

We also investigated if, in life span-extending manipulations, there is a negative correlation between the *t50* of the controls and the life extension effects (measured as the percentage *t50* increase in the experimental cohort). Indeed, there is a moderate (*r^2^* = 0.30) but statistically significant negative correlation (*P*-value = 0.002; *n* = 33), suggesting that effect sizes in longevity experiments could be influenced by the short life span of the controls.

There was a strong negative correlation between α and ln(*R~0~*): *r^2^* = 0.93 for life span-extending manipulations and *r^2^* = 0.53 (after removing *Pasg*, which is an outlier; see [Table 4](#t4){ref-type="table"}) for life span-reducing manipulations. As such, increases in aging-independent mortality tend to be accompanied by a slower demographic aging rate, as observed before ([@bib14]).

Combining earlier results ([@bib14]) with the current analysis allows greater power to evaluate the usefulness of demographic analysis in aging. Therefore, we employed a data set with 63 manipulations of longevity: 41 life span-extending plus 22 life span-reducing manipulations (note that for this analysis we excluded manipulations for which we lacked demographic aging parameters for controls, which resulted in the exclusion of six life-reducing interventions from the previous analyses). Of note, we found that by and large an impact on longevity is caused by a change in the aging-independent mortality, which is observed both for life-extending ([Figure 3, A and B](#fig3){ref-type="fig"}) and life-reducing manipulations ([Figure 3, C and D](#fig3){ref-type="fig"}). And confirming the above-mentioned results, we observed that decreases in ln(*R~0~*) correlated with increases in α for life span-extending (*r^2^* = 0.64) and life span-reducing manipulations (*r^2^* = 0.64).

![Comparison between control (*x*-axis) and experimental cohorts (*y*-axis) for α in life-extending manipulations (A), *R~0~* in life-extending manipulations (B), α in life span-reducing manipulations (C), and *R~0~* in life span-reducing manipulations (D).](1617fig3){#fig3}

Discussion {#s10}
==========

The Gompertz function, used here to fit only the linear phase of the mortality trajectories, allowed for simple comparison between studies as it is described by just two parameters. Although it has been found that more complex adaptations of the Gompertz function \[*e.g.*, the logistic model ([@bib44])\] provide a better fit for some whole-mortality curves ([@bib14]; [@bib67]), the sample sizes usually reported for mouse life span experiments are insufficiently large to apply these models with sufficient accuracy.

Longevity is influenced by a number of factors, including age-independent mortality, age at the onset of senescence, and demographic rate of aging. In this study, we employed the Gompertz model to fit published mouse survival data and generate parameters that could be used to identify genes that influence the demographic rate of aging. Overall, only 7/54 genes were found to have a statistically significant effect on the demographic rate of aging as expected from longevity manipulations. These results suggest that only a relatively small proportion of interventions reported to affect longevity in mice do so through directly influencing the demographic rate of aging, in line with other, albeit smaller, studies ([@bib14]; [@bib67]; [@bib21]; [@bib26]). Surprisingly, 20/54 genes had a statistically significant impact on the demographic rate of aging in the opposite direction than would be expected for the published longevity effects. One possible explanation is that many mutations impacted on various parameters affecting longevity in nonlinear ways, and indeed we observed that increases in aging-independent mortality correlated with a slower demographic aging rate. For instance, *Sirt1* deficiency extended life span but increased the demographic rate of aging; its effect appeared to be exerted instead by delaying the age of onset of mortality rate escalation. This highlights the complex relationship between life span and the demographic rate of aging. It is also possible that other confounding factors, like censored data or noise, in particular for smaller cohorts, influenced these results.

Another caveat of our approach concerns the number of mice used in some of the original studies, which ranged from 10 to 146 animals per cohort. While research reported here has attempted to compensate for this by using the Gompertz equation, which allows for small sample sizes, one cannot escape the low statistical power that accompanies such small sample sizes. Interestingly, caloric restriction has been shown to significantly retard the demographic rate of aging, but this was a large study with \> 200 animals in total ([@bib14]). Therefore, caution must be taken when interpreting some of the results detailed here from studies with small sample sizes. Indeed, we observed that, in smaller experimental cohorts, subjective decisions in estimating Gompertz parameters can significantly affect the results, *e.g.*, for *Htr1b*−/−.

Potential caveats of our analysis include the subjectivity of deciding the time at which analysis should begin and problems in the reporting of mouse survival data. As reviewed in detail by [@bib72], mouse longevity studies should adhere to certain standards to provide useful data. These include a sufficiently large cohort, high standards of pathogen-free animal husbandry to eliminate deaths from infectious disease, and separate reporting of male and female survival data. Unfortunately, life span data are often incompletely reported and, in many of the studies analyzed in this work, male and female data were not presented separately. Censoring of mice that died before a certain age in some studies may also have introduced noise into our results.

Our results provide insights regarding the role in aging of various genes. Of particular interest are the findings concerning *Casp2* and *Cisd2*. We found that *Casp2* deficiency increased the demographic rate of aging, which has not previously been proposed. *Casp2* −/− mice had a similar median life span to WT and did not show elevated tumor incidence ([@bib69]). Besides, our results indicate that persistent expression of *Cisd2* significantly reduced the demographic rate of aging. Further investigation has since strengthened the case for Cisd2\'s involvement in regulating the rate of aging by showing that it is involved in autophagy, mitochondrial function, and adipocyte differentiation ([@bib61]), showing that it may influence several pathways thought to be important for aging.

Conclusions {#s11}
-----------

Overall, we performed a demographic analysis of 54 mouse studies in which genetic manipulations significantly extended or reduced life span. We also combined our results with a previous report to perform an analysis of factors associated with longevity in mice. To our knowledge, this is the largest such study to date. Our main conclusions are: (1) most genetic manipulations of longevity in mice do so by modulating aging-independent mortality; (2) there is substantial variation in the life span of controls of the same strain across experiments; (3) studies in which the life span of the controls is short have a greater life span increase, emphasizing the importance of having adequate control groups; (4) mouse life span studies employing small cohorts can yield unreliable results; (5) life span-reducing experiments tend to be noisier and more difficult to analyze for demographic parameters than life-extending experiments; and (6) a greater aging-independent mortality is usually accompanied by a slower demographic aging rate.

Supplementary Material {#s12}
======================

Supplemental material is available online at [www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1](http://www.genetics.org/lookup/suppl/doi:10.1534/genetics.118.300821/-/DC1).
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